| |||||||||
This excerpt taken from the TPTX 8-K filed Dec 15, 2009. WHEREAS, in order to induce
Agent to continue to serve in his capacity as described above, the Company has
determined and agreed to enter into this Agreement with Agent.
This excerpt taken from the TPTX 10-K filed Mar 29, 2007. Whereas,
pursuant to Section 27 of the Rights Agreement, the Company and the Rights
Agent may from time to time supplement or amend the Rights Agreement in
accordance with the provisions of Section 27 thereof and the Company
desires and directs the Rights Agent to so amend the Rights Agreement.
In consideration of the foregoing premises and mutual agreements set forth in the Rights Agreement and this Amendment, the parties hereto agree as follows: 1. Effective as of the Reincorporation Effective Time, the Certificate of Designation of Axonyx Inc. attached as Exhibit A to the Rights Agreement, shall be replaced in its entirety by the Certificate of Incorporation of TorreyPines Therapeutics, Inc. in the form attached hereto as Exhibit A. 2. Effective as of the Reincorporation Effective Time, Section 32 of the Rights Agreement, is hereby modified and amended to read in its entirety as follows: “Governing Law. This Agreement, each Right and each Rights Certificate issued hereunder shall be deemed to be a contract made under the laws of the State of Delaware and for all purposes shall be governed by and construed in accordance with the laws of such state applicable to contracts to be made and to be performed entirely within such state.” 3. Except as expressly amended hereby, the Rights Agreement remains in full force and effect in accordance with its terms. By executing this Amendment below, the Company certifies that this Amendment has been executed and delivered in compliance with the terms of Section 27 of the Rights Agreement. This Amendment shall become effective as of the Reincorporation Effective Time.
4. All acts and things necessary to make this Amendment a valid agreement according to its terms have been done and performed, and the execution and delivery of this Amendment by the Company and the Rights Agent have been in all respects authorized by the Company and the Rights Agent. 5. This Amendment to the Rights Agreement shall be governed by and construed in accordance with the laws of the State of Delaware. 6. This Amendment to the Rights Agreement may be executed in any number of counterparts and each of such counterparts shall for all purposes be deemed an original, and all such counterparts shall together constitute but one and the same instrument. 7. Except as expressly set forth herein, this Amendment to the Rights Agreement shall not by implication or otherwise alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Rights Agreement, all of which are ratified and affirmed in all respects and shall continue in full force and effect. 8. If any term, provision, covenant or restriction of this Amendment is held by a court of competent jurisdiction or other authority to be invalid, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions of this Amendment shall remain in full force and effect. 9. Capitalized terms used herein but not defined shall have the meanings given to them in the Rights Agreement.
IN WITNESS WHEREOF, the parties hereto have caused this Amendment to the Rights Agreement to be duly executed as of the day and year first above written.
These excerpts taken from the TPTX 8-K filed Oct 10, 2006. WHEREAS, Eisai
wishes to participate in such project in the manner and to the extent described
below, to obtain the first negotiation right with respect to any and all
intellectual property of Neurogenetics claiming, disclosing or covering any
Validated Compounds (as defined below), or the manufacture, use, sale, offer
for sale or import of any Validated Compounds, arising out of or resulting from
such project and to obtain a right of first refusal with respect to any Term
Sheet (as defined below), on the terms set forth in this Agreement.
WHEREAS, Eisai
and TPTX acknowledge that certain data set forth in Exhibit A arose from
or arose out of research activities under the Collaboration Agreement.
WHEREAS, Neurogenetics
and LSRI desire to enter into a collaborative relationship for research and
development of the Licensed Compound and/or the Additional Compound on the
terms set forth herein.
| EXCERPTS ON THIS PAGE:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
